Baker BROS. Advisors LP Sells 5,845,706 Shares of DBV Technologies S.A. (NASDAQ:DBVT)

Baker BROS. Advisors LP reduced its position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 80.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,461,425 shares of the company's stock after selling 5,845,706 shares during the quarter. Baker BROS. Advisors LP owned approximately 7.10% of DBV Technologies worth $4,516,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Boxer Capital Management LLC purchased a new stake in shares of DBV Technologies during the fourth quarter worth about $154,000. 71.74% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on DBVT. HC Wainwright increased their price objective on DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a report on Monday. JMP Securities boosted their price objective on shares of DBV Technologies from $10.00 to $15.00 and gave the company a "market outperform" rating in a research report on Thursday, May 1st. Finally, StockNews.com initiated coverage on shares of DBV Technologies in a research report on Thursday, May 1st. They issued a "hold" rating for the company.

DBV Technologies Price Performance

DBVT stock traded up $0.11 during midday trading on Wednesday, hitting $9.50. The stock had a trading volume of 93,893 shares, compared to its average volume of 185,380. The business has a 50-day moving average of $6.58 and a two-hundred day moving average of $4.75. The firm has a market cap of $260.21 million, a price-to-earnings ratio of -2.11 and a beta of -0.66. DBV Technologies S.A. has a 52-week low of $2.20 and a 52-week high of $9.90.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The business had revenue of $0.51 million during the quarter. Research analysts predict that DBV Technologies S.A. will post -7.05 earnings per share for the current year.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.